Liraglutide-coated nanoparticles target pancreatic beta cells for diabetes imaging and drug delivery | Research

The takeaway

Liraglutide-conjugated upconversion nanoparticles successfully target GLP-1 receptors on pancreatic beta cells, with intramuscular injection doubling pancreatic accumulation versus IV, demonstrating potential for diabetes theranostics.

2x pancreatic targeting
Intramuscular injection of liraglutide-conjugated nanoparticles doubled pancreatic accumulation compared to IV, with confirmed beta cell uptake

What the researchers found

Liraglutide-conjugated nanoparticles bind GLP-1 receptors on beta cells, increase insulin secretion from isolated islets, and show 2x greater pancreatic accumulation via intramuscular vs IV injection. Receptor-mediated internalization confirmed by confocal microscopy and elemental analysis.

Why it matters

Targeted delivery of diabetes drugs specifically to beta cells could improve treatment efficacy while reducing systemic side effects. Combining drug delivery with imaging capabilities enables monitoring of treatment response.

How the study worked

Nanoparticle synthesis and characterization, GLP-1 receptor binding studies, insulin secretion assays on isolated Langerhans islets, biocompatibility testing, in vivo fluorescence imaging in mice, and confocal microscopy for cellular uptake.

What this study cannot tell us

Preclinical mouse study. Scalability and manufacturing costs unclear. Long-term safety of rare-earth nanoparticles needs evaluation. Clinical translation pathway undefined.

How to read the evidence

Preclinical proof-of-concept with thorough characterization and in vivo validation. Very early stage for clinical translation.

When this study was published

Published in 2025; represents current nanotechnology approaches to peptide-targeted drug delivery.

The bigger picture

This represents an advance in precision diabetes medicine—using the peptide drug itself as a targeting ligand for nanoparticle delivery. If translatable, this could enable personalized diabetes monitoring and targeted therapy.

Questions still open

How do these nanoparticles compare to unmodified liraglutide for glycemic control in vivo?
What is the long-term fate and clearance of rare-earth nanoparticles in the body?
Could this platform deliver other diabetes drugs or gene therapies to beta cells?

Common questions

How do these nanoparticles find beta cells?

The nanoparticles are coated with liraglutide, which naturally binds to GLP-1 receptors on insulin-producing beta cells. This acts as a "homing signal" that directs the particles specifically to the pancreas, where they are internalized by the target cells.

Could this improve diabetes treatment?

Potentially. By delivering drugs directly to beta cells and simultaneously enabling imaging, these nanoparticles could allow doctors to both treat and monitor diabetes in a more targeted way. However, this is very early research and many steps remain before human application.

Read the original research

Liraglutide-Conjugated Poly(methyl vinyl ether-alt-maleic acid)-Coated Core-Shell Upconversion Nanoparticles for Theranostics of Diabetes.

ACS applied materials & interfaces, 17(30), 42863-42876

View on PubMed ↗Publisher’s paper ↗

Citation

Shapoval, Oleksandr; Engstová, Hana; Šlouf, Miroslav; Kočková, Olga; Dlasková, Andrea; Jabůrek, Martin; Halili, Aminadav; Mozheitová, Alexandra; Jirák, Daniel; Ježek, Petr; Horák, Daniel. (2025). Liraglutide-Conjugated Poly(methyl vinyl ether-alt-maleic acid)-Coated Core-Shell Upconversion Nanoparticles for Theranostics of Diabetes.. ACS applied materials & interfaces, 17(30), 42863-42876. https://doi.org/10.1021/acsami.5c11275